MDTB is a spin-off from the Center for Regenerative Therapies Dresden (CRTD)’s GMP-Facility, which has long-standing expertise in the production of Mesenchymal Stromal Cells (MSC), including procedures for the isolation, expansion, cryopreservation and thawing of MSC and its compassionate use in several clinical settings at the University Hospital Dresden – one of the leading hospitals in the field of regenerative therapies.

The mission of MDTB is to provide allogeneic, off-the-shelf MSC products at high quality for clinical trials in adults, children and neonates for various indications based on patented isolation protocols utilizing umbilical cord tissue.

One crucial aim of MDTB is to support the international collaboration using Mesenchymal Stromal Cells (MSC) to Ameliorate Severe Complications of Diseases (MASC-Collaboration), which set out to make MSC-based regenerative therapies an integral part of clinical routine in large patient groups within a decade.

Led by the University Hospital Dresden and the Technische Universität Dresden, the MASC-Collaboration dedicates the combined expertise and enthusiasm of leading scientists, clinicians, patient organizations (as the European Foundation for the Care of Newborn Infants EFCNI) and industry.

For any further information or questions please feel free to contact us.

Direct contact:

Erste-Hilfe-Set des Körpers

Sächsische Zeitung

Dresdner Wissenschaftler können jetzt therapeutisch hochpotente Zellen in großer Menge gewinnen. Ein Meilenstein für Patienten.

MDTB Cells GmbH, Meißner Straße 55, 01445 Radebeul